Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysis.

Autor: Abouelmagd ME; Faculty of Medicine, Cairo University, Cairo, Egypt. moaz_s_sayed@studendts.kasralainy.edu.eg., Abdelmeseh M; Faculty of Medicine, Alexandria University, Alexandria, Egypt., Elrosasy A; Faculty of Medicine, Cairo University, Cairo, Egypt., Saad YH; Faculty of Medicine, Mansoura University, Mansoura, Egypt., Alnajjar AZ; Faculty of Medicine, Al- Al-Azhar University, Gaza, Palestine., Eid M; Faculty of Medicine, October 6Th University, Cairo, Egypt., Hassan A; Faculty of Medicine, Al-Azhar University, Damietta, Egypt., Abbas A; Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Jazyk: angličtina
Zdroj: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2024 Nov; Vol. 45 (11), pp. 5261-5270. Date of Electronic Publication: 2024 May 25.
DOI: 10.1007/s10072-024-07583-9
Abstrakt: Background: The management of Alzheimer's disease (AD) poses considerable challenges, necessitating the pursuit of innovative therapeutic approaches. Recent research has spotlighted the promising role of phosphodiesterase type 5 inhibitors (PDE5Is) in reducing the prevalence of AD, utilizing their vasodilatory properties to suggest a potential neuroprotective effect. This meta-analysis and systematic review aims to assess the relationship between the use of PDE5Is and the risk of AD.
Methods: A detailed examination was carried out across several electronic databases till March 2024, including PubMed, Web of Science, Scopus, CENTRAL, and Embase. The focus was on identifying studies that compare the occurrence of AD among PDE5I users vs non-users. Through a random-effects model, pooled hazard ratios (HRs) were calculated, in alignment with guidelines from the Cochrane Handbook for Systematic Reviews and Meta-Analysis and the PRISMA standards.
Results: This analysis included six studies, cumulating a participant count of 8,337,313, involving individuals treated with sildenafil, tadalafil, and vardenafil, against a control group undergoing other or no treatments. The cumulative HR for AD risk among PDE5I users versus the control group was 0.53 (95% CI: 0.32-0.86, p = 0.008), signaling a markedly reduced likelihood of AD development in the PDE5I group. Particularly, sildenafil usage showed a significant risk reduction (HR: 0.46, 95% CI: 0.31-0.70, p < 0.001), while findings for tadalafil and vardenafil were not significant. Test of subgroup differences found no difference between male and female participants in the risk of AD.
Conclusions: Our findings suggest that the use of PDE5Is is associated with a reduced risk of AD, highlighting its potential as a protective agent against neurodegenerative diseases. Given the very low quality of evidence and the heterogeneity among the included studies, further high-quality research is warranted to confirm these findings and elucidate the underlying mechanisms. Register number PROSPERO 2024: CRD42024522197.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: